Targeting the Inflammation–Metabolism Axis in MGUS: Causal Roles of CXCL10 Mediated by Blood Metabolites
Open Access
- 1 January 2025
- journal article
- Published by Wiley in Mediators of Inflammation
- Vol. 2025 (1)
Abstract
Background: Inflammatory cytokines have been implicated in monoclonal gammopathy of undetermined significance (MGUS), but their causal mechanisms remain unclear. Metabolites play pivotal roles in plasma cell dysregulation, however, their potential mediation effects between cytokines and MGUS are unexplored. We aimed to elucidate causal relationships between inflammatory cytokines and MGUS and identify metabolite‐mediated pathways. Methods: Using genome‐wide association study (GWAS) summary statistics, we performed bidirectional two‐sample Mendelian randomization (MR) to assess causality between 91 inflammatory cytokines and MGUS. A two‐step MR approach was employed to investigate metabolite mediation using data from 1400 blood metabolites. Sensitivity analyses addressed pleiotropy and reverse causality (IVs: p < 1 × 10 −5 , F ‐statistic > 10). Results: MR analysis identified CXCL10 (OR = 2.12, 95% CI: 1.06–4.23, p = 0.034) and IL‐6 (OR = 3.61, 95% CI: 1.22–10.65, p = 0.020) as causal risk factors for MGUS. We also found Threonate (OR = 2.24, 95% CI: 1.06–4.75, p = 0.035), X‐22776 (OR = 3.45, 95% CI: 1.37–8.67, p = 0.009) and glucose to sucrose ratio (OR = 2.89, 95% CI: 1.18–7.07, p = 0.020) were associated with increased MGUS risk, while N‐acetylputrescine to (N(1) + N(8))‐acetylspermidine ratio (OR = 0.65, 95% CI: 0.43–0.98, p = 0.039) showed protective effects. Mediation analysis revealed 2 metabolites Threonate and X‐22776 mediating CXCL10’s effect on MGUS. Threonate mediated 11.2% ( β = 0.08, p = 0.014) and X‐22776 mediated 17.7% ( β = 0.13, p = 0.028) of CXCL10’s total effect. Sensitivity analyses confirmed robustness (no pleiotropy: MR‐Egger intercept p > 0.05; Cochran’s Q p > 0.05). Conclusion: This study deeply reveals the mechanism by which inflammatory cytokines affect the pathogenesis of MGUS through metabolite‐mediated pathways, providing new potential targets for the early diagnosis and treatment of MGUS. In the future, other inflammatory cytokines and metabolites that may be related to the pathogenesis of MGUS can be further explored, and the interactions and potential mechanisms between them can be further studied to provide a more comprehensive theoretical basis and practical guidance for the prevention and treatment of MGUS.Keywords
Funding Information
- Natural Science Foundation of Jiangsu Province (BK20240310)
This publication has 45 references indexed in Scilit:
- Interleukin-6 in neuroimmunological disorders: Pathophysiology and therapeutic advances with satralizumabAutoimmunity Reviews, 2025
- Mutational Landscape of Bone Marrow CD19 and CD138 Cells in Waldenström Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM MGUS)Cancer Medicine, 2024
- Associations Between Patient Characteristics and Progression to Multiple Myeloma Among Patients With Monoclonal Gammopathy of Undetermined Significance: A Systematic ReviewClinical Lymphoma Myeloma and Leukemia, 2024
- Sulforaphane modulates some stress parameters in TPT-exposed Cyprinus carpio in relation to liver metabolomeEcotoxicology and Environmental Safety, 2024
- Di-2-ethylhexyl phthalate (DEHP) induced lipid metabolism disorder in liver via activating the LXR/SREBP-1c/PPARα/γ and NF-κB signaling pathwayFood and Chemical Toxicology, 2022
- Skelettveränderungen bei PlasmazelldyskrasienDer Radiologe, 2021
- Mendelian randomisation for mediation analysis: current methods and challenges for implementationEuropean Journal of Epidemiology, 2021
- Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of CrbnExperimental Hematology, 2021
- Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple MyelomaJAMA Oncology, 2019
- CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implicationsCytokine & Growth Factor Reviews, 2011